Work

Phase I Study Of LY2784544, a JAK2 Selective Inhibitor, In Patients With Myelofibrosis (MF), Polycythemia Vera (PV), and Essential Thrombocythemia (ET)

Year: 2013

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v122.21.665.665

Authors: Srdan Verstovsek, Ruben A Mesa, Mohamed E Salama, Jennifer L K Giles, Celine Pitou, Annamaria Hayden Zimmermann, Gregory L Price, Richard A Walgreen, Josef Prchal

Institutions: The University of Texas MD Anderson Cancer Center, Mayo Clinic in Arizona, University of Utah, Eli Lilly (United States)

Language: English

Topic: Myeloproliferative Neoplasms: Diagnosis and Treatment

Subfield: Genetics (clinical)

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W150400455

FWCI: 3.119

Cites:

Cited by: 24

Related to: 10